Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Perjeta, Polivy, Tecentriq, and Phesgo; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept for immunosuppressant; Edirol, an osteoporosis agent; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi for spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Ronapreve, an anti-SARS-CoV-2 monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo-ku, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.
तुलना करने के लिए मीट्रिक्स | 4519 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध4519पीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | 28.9x | 21.8x | −0.6x | |
PEG अनुपात | 1.93 | −0.37 | 0.00 | |
क़ीमत/बुक | 6.2x | 1.5x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 9.8x | 1.9x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | 15.2% | 14.0% | 40.6% | |
उचित मूल्य अपसाइड | अनलॉक करें | 15.0% | 7.1% | अनलॉक करें |